The State of Ohio Board of Pharmacy is committed to protecting the health and safety of Ohioans during the COVID-19 outbreak. The Board posted a document on its website that provides COVID-19 guidance and response efforts, including the issuance of waivers to assist licensees in addressing operational needs. Waivers can be found starting on page 5 of this document: www.pharmacy.ohio.gov/COVID.

For more information on the state’s efforts to address coronavirus, visit www.coronavirus.ohio.gov or call 1-833-4-ASK-ODH.

COVID-19 Vaccine Booster Communications Toolkit

Ohio has reached a point in the pandemic where it is critically important for all eligible Ohioans in all age groups who haven’t already gotten a COVID-19 vaccine booster shot to get one – especially Ohioans age 50+ who are at greatest risk of severe illness, hospitalization, and death.

Today, the Board posted a communications toolkit for community partners on its website that equips users in communicating the importance of getting a COVID-19 booster shot, answering technical questions, and providing locations where patients may receive a booster shot. The toolkit is designed for stakeholders to promote the importance of booster doses using their social media channels with sample text and graphics, or on their websites or in their publications.

Please note that if you choose to unsubscribe from receiving emails, this unsubscribes you from all emails that are sent by the State of Ohio Board of Pharmacy, including renewal reminders. If you believe you have unsubscribed in error, please email contact@pharmacy.ohio.gov for assistance. If you would like to change the email address, please log into your eLicense Ohio account to update the email address on file.
Public Health Communications Collaborative
Resources for COVID-19

https://publichealthcollaborative.org/
Mayo Clinic COVID-19 Tool Kit

Boosting COVID-19 Vaccine Confidence: An Educational Toolkit for Providers

https://primeinc.org/online/boosting-covid-19-vaccine-confidence-educational-toolkit-providers

Amelia G. Johnson, DrPH*; Avinka B. Amin, PhD†; Akilah R. Ali, MPH‡; Brooke Hoots, PhD; Betsy L. Cadwell, PhD; Shivani Arora, MPH; Tigran Avoufidjian, PhD§; Abiola O. Awoseso, DVM; Jason Barnes, MAB; Nagla S. Bayoumi, DrPH; Katherine Busen, MPH; Carolyn Chang, MPH; Dina Cima, PhD; Molly Crockett, MPH; Alejandro Croman, MPH; Sherri Davidson, PhD; Elizabeth Davis, MA; Janelle Delgado, PhD; Vajera Dorabawila, PhD; Cherie Drenzek, DVM; Leah Eisenstein, MPH; Hannah E. Fast, MPH; Ashley Gent, MPH; Julie Hand, MS; Michael Hofer, PhD; Corinne Holtzman, MPH; Amanda Jara, DVM; Amanda Jones, MPH; Ishaar Kamali-Ahmed, PhD; Sarah Kangas, MPH; FNU Kanishka, MPH; Ramandeep Kaur, PhD; Saadia Khan, MPH; Justice King, MSc; Samantha Kirkendall, MS; Anna Kloulova, MPH; Anna Kocharian, MS; Frances Y. Kwon, MPH; Jacqueline Logan, MPH; Casey Lyons, MPH; Shelby Lyons, MPH; Andrea May, PhD; Donald McCormick, MSHI; Erica Mendoza, MAS; Lauren Milroy, MPH; Allison O’Donnell, MPH; Melissa Pike, MPH; Sargis Pogosjans, MPH; Amy Sauer, MPH; Jessica Sell, MPH; Elizabeth Smith, MPH; Daniel M. Sosin, MD; Emma Stanislawski, MPH; Malaika Steege, PhD; Meagan Stephenson, MPH; Allen Stout, MS; Kyle Strand; Buddh P. Tilakaratne, PhD; Kathryn Turner, PhD; Hailey Vest, MPH; Sydney Warner, MS; Caleb Wiedeman, MPH; Allison Zaldivar, MPH; Benjamin J. Silk, PhD; Heather M. Scobic, PhD

On January 21, 2022, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr).

Previous reports of COVID-19 case, hospitalization, and death rates by vaccination status indicate that vaccine protection against infection, as well as serious COVID-19 illness for some groups, declined with the emergence of the B.1.617.2 (Delta) variant of SARS-CoV-2, the virus that causes COVID-19, and waning of vaccine-induced immunity (1–4). During August–November 2021, CDC recommended additional primary COVID-19 vaccine doses among immunocompromised persons and booster doses among persons aged ≥18 years (5). The SARS-CoV-2 B.1.1.529 (Omicron) variant emerged in the United States during December 2021 (6) and by December 25 accounted for 72% of sequenced RNA or antigen was detected in a respiratory specimen collected ≥14 days after completing the primary series of a COVID-19 vaccine with Food and Drug Administration (FDA) approval or emergency use authorization. The COVID-19 case definition, including criteria to distinguish a new case from an existing case, is per the July 2021 update to the national standardized surveillance case definition and national notification for 2019 novel coronavirus disease (COVID-19) (21-01) (https://nccd.cdc.gov/case-definition/coronavirus-disease-2019-2021/). Fully vaccinated persons were those with a completed primary series of doses of the Pfizer-BioNTech or Moderna mRNA vaccine or a single dose of the Janssen vaccine (https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html). A COVID-19 case in an unvaccinated person occurred when the person did not receive any FDA-approved COVID-19 vaccine dose before the specimen collection date. Cases were excluded in partially vaccinated persons who received at least one FDA-authorized or approved vaccine dose but did not complete a primary series ≥14 days before collection of a respiratory specimen with SARS-CoV-2 RNA or antigen detected. Ascertainment vaccination status for COVID-19 patients through active linkage of case surveillance and immunization information systems typically assumes that cases among persons who are unmatched to the registry are unvaccinated. This analysis represents the combined impact of the Pfizer-BioNTech, Moderna, and Janssen COVID-19 vaccines, which had different clinical efficacies against confirmed infection. Information on different FDA-authorized and approved COVID-19 vaccine products, including clinical efficacy, is available online. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines.html


A COVID-19 case in a fully vaccinated person with a booster dose occurs when a person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of at least one additional or booster dose of any COVID-19 vaccine on or after August 13, 2021 (this definition does not distinguish between vaccine recipients who are immunocompromised and those who are unimmunocompromised and receiving a booster dose).
REVIEW

Vitamins, supplements and COVID-19: a review of currently available evidence

Lauren L Speakman, Sarah M Michienzi, Melissa E Badowski
Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy, Chicago, IL

Abstract

Background: In the midst of the COVID-19 pandemic, there has been an information overload of health data (both accurate and inaccurate) available to the public. With vitamins and supplements being readily accessible, many have turned to using them in an effort to combat the virus. The purpose of this review was to analyse clinical trials regarding vitamins and supplements for the treatment of COVID-19 infections.

Methods: Articles were identified through a literature search utilizing online databases and bibliographic review.

Results: A total of seven articles were identified for review. All articles evaluated the use of vitamins and supplements for the treatment of COVID-19. Drug therapies included oral vitamin D, intravenous and oral vitamin C, oral vitamin D/magnesium/ vitamin B12, oral zinc, oral combination zinc/ascorbic acid, and intravenous alpha-lipoic acid. The end points of each study varied, including the Sequential Organ Failure Assessment score, mortality, rate of intensive care unit (ICU) admissions, negativity of COVID-19 tests, oxygen requirements, and symptom burden.

Conclusion: Of the vitamins and supplements that were studied, vitamin D presented the most promising data demonstrating significant decreases in oxygen requirements, need for ICU treatment, SARS-CoV-2 RNA test positivity, and mortality. All of these benefits were exhibited in hospitalized patients. Other vitamins and supplements that were evaluated in studies did not demonstrate any statistically significant benefits. Common shortcomings of the articles included generally small sample sizes, varying sites of study (which could determine the virus variant), a lack of standard of care as background therapy, and utilization of doses that were higher than standard.

Keywords: coronavirus, COVID-19, SARS-COV-2, severe acute respiratory syndrome coronavirus, supplement, vitamin.

Citation

Introduction

SARS-CoV-2, the virus causing COVID-19, was first reported to the WHO on 31 December 2019 and was declared a global pandemic on 11 March 2020.1–3 To date, there have been more than 229 million reported cases and 4.7 million deaths of COVID-19 infections, with the exception of vaccines. Throughout the course of this pandemic, many therapies have been proposed as having utility, with many, but not all, falling short of providing meaningful results in clinical trials. Some proposed therapies have never undergone clinical trials, and medical claims are being made based on theoretical or anecdotal evidence.17 Since the public concern regarding articles that review in progress studies...
Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus

Damien J. Downes1, Amy R. Cross2,3, Peng Hua4,1,13, Nigel Roberts1, Ron Schwessinger1,3, Antony J. Cutler4,12, Altar M. Munic5, Jill Brown6, Olga Mielczarek4, Carlos E. de Andrea6, Ignacio Melero7, COVID-19 Multi-omics Blood ATlas (COMBAT) Consortium*, Deborah R. Gill5, Stephen C. Hyde5, Julian C. Knight3,5, John A. Todd4, Stephen N. Sansom10, Fadi Issa2,11,10, James O. J. Davies2,11 and Jim R. Hughes1,3

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) pandemic has caused millions of deaths worldwide. Genome-wide association studies identified the 3p21.31 region as conferring a twofold increased risk of respiratory failure. Here, using a combined multomics and machine learning approach, we identify the gain-of-function risk A allele of an SNP, rs17713054>G>A, as a probable causative variant. We show with chromosome conformation capture and gene-expression analysis that the rs17713054-affected enhancer upregulates the interacting gene, leucine zipper transcription factor like 1 (LZTFL1). Selective spatial transcriptomic analysis of lung biopsies from patients with COVID-19 shows the presence of signals associated with epithelial–mesenchymal transition (EMT), a viral response pathway that is regulated by LZTFL1. We conclude that pulmonary epithelial cells undergoing EMT, rather than immune cells, are likely responsible for the 3p21.31-associated risk. Since the 3p21.31 effect is conferred by a gain-of-function, LZTFL1 may represent a therapeutic target.

The COVID-19 pandemic is estimated to have caused over 4.6 million deaths so far1,2. The predominant cause of mortality is pneumonia and severe acute respiratory distress syndrome. However, COVID-19 can cause multiple organ failure through cytokine release, microvascular and macrovascular thrombosis, endothelial damage, acute kidney injury and myocarditis3,4. Genome-wide association studies (GWAS) are important for identifying candidate genes and pathways that predispose to complex diseases5; genetically validated drug targets are more likely to lead to approved drugs6. Two large GWAS were carried out to determine whether common variants drive susceptibility to severe COVID-19 (refs. 7,8). Both studies identified a region of chromosome 3p21.31 as having the strongest association, while a third study also identified this locus as conferring susceptibility to infection8. The 3p21.31 risk haplotype, which arises from Neanderthal DNA9 and is currently unexplained with regards to the causal variant(s), causalgene(s) and specific role in COVID-19, confers a twofold increased risk of respiratory failure from COVID-19 (ref. 10) and an over twofold increased risk of mortality for individuals under 60 (ref. 11). Additionally, the risk variants at this locus are carried by >60% of individuals with South Asian ancestry (SAS), compared to 15% of European ancestry (EUR) groups, partially explaining the ongoing higher death rate in this population in the UK11,12.

Identifying the causal gene(s) and mechanism(s) behind GWAS hits poses several challenges. First, a causative variant is usually in linkage disequilibrium (LD) with many other variants and these can take different forms (SNPs, insertions, deletions and structural polymorphisms). Second, the genetic signals are completely cell type-agnostic, which makes it challenging to identify appropriate experimental models for further investigation. Third, there are mul-tiple mechanisms by which variants can have an effect. Alteration of the protein-coding sequence or DNA splicing both of which are relatively straightforward to disentangle, account for fewer than 20% of associations in polygenic disease13. The remaining variants and their target gene(s) can be very difficult to decode. Many are thought to lie within cis-regulatory elements14, such as enhancers, which are short DNA sequences that often control tissue- and developmental-stage-specific gene expression. Deciphering the vari-ants that affect enhancers is challenging because many enhancers are only active in specific cell types or at specific times; enhancers are often distant in the linear DNA sequence (often 104–106 base pairs (bp)) from the genes they control and the effects of sequence changes are not straightforward to predict.

We developed a comprehensive platform for decoding the effects of sequence variation identified by GWAS15 (Extended Data Fig. 1a). This combines computational and wet lab approaches to delineate

1Department of Medicine, Medical Research Council Molecular Haematology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. 2Department of Psychology, Medical Research Council Weatherall Institute of Molecular Medicine Centre for Computational Biology, University of Oxford, Oxford, UK. 3Nuffield Department of Medicine, Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK. 4Nuffield Department of Medicine, University of Oxford, Oxford, UK. 5Department of Medicine, Nuffield Division of Clinical Lab Sciences, Radcliffe University of Oxford, Oxford, UK. 6Department of Pathology, Clinic University of Navarra, Pamplona, Spain. 7Division of Immunology and Immunotherapy, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain. 8Chinese Academy of Medical Science Oxford Institute, University of Oxford, Oxford, UK. 9National Institute for Health Research Oxford Biomedical Research Centre, Oxford, UK. 10Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. 11Oxford University Hospitals National Health Service Foundation Trust, Oxford, UK. 12Present address: GlaxoSmithKline, Stevenage, UK. 13These authors contributed equally: Amy R. Cross, Peng Hua. *A list of members and their affiliations appears in the Supplementary Information.

e-mail: james.davies@imm.ox.ac.uk; jim.hughes@imm.ox.ac.uk
Aging, obesity, and diabetes are major risk factors for the severe progression and outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (coronavirus disease 2019 [COVID-19]), but the underlying mechanism is not yet fully understood. In this study, we found that the SARS-CoV-2 spike protein physically interacts with cell surface GRP78, which promotes the binding to and accumulation in ACE2-expressing cells. GRP78 was highly expressed in adipose tissue and increased in humans and mice that were older, obese, and had diabetes. The overexpression of GRP78 was attributed to hyperinsulinemia in adipocytes, which was in part mediated by the stress-responsive transcription factor XBP-1s. Management of hyperinsulinemia by pharmacological approaches, including metformin, sodium–glucose cotransporter 2 inhibitor, or β-adrenergic receptor agonist, decreased GRP78 gene expression in adipose tissue. Environmental interventions, including exercise, calorie restriction, fasting, or cold exposure, reduced the gene expression of GRP78 in adipose tissue. This study provides scientific evidence for the role of GRP78 as a binding partner of the SARS-CoV-2 spike protein and ACE2, which might be related to the severe progression and outcome of COVID-19 in older and obese patients with diabetes. The management of hyperinsulinemia and the related GRP78 expression could be a therapeutic preventative target.

The outbreak of the novel β-coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, coronavirus disease 2019 (COVID-19), has rapidly spread worldwide and, to date, has resulted in over 169,000,000 human infections and more than 3,500,000 deaths. The development of SARS is the major factor for serious progression and mortality in COVID-19 patients (1). Emerging studies have shown that there is an increased risk of poor outcomes with increasing age, obesity, visceral adiposity, and diabetes (2–4), but the linked molecular mechanisms have not yet been explained. In this severe pandemic, further scientific information and therapeutic targets are required.

While adipose tissue plays an important role in the regulation of energy homeostasis, its abnormalities have harmful effects on systemic healthy states. The aging- or obesity-associated pathological expansion of adipose tissue, especially in the visceral region, contributes to the development of various metabolic diseases and their complications (5–8). Hyperinsulinemia, a chronic state of high insulin levels, is commonly found in older or obese patients (9,10) and causes detrimental cellular stress in adipose tissue, such as reactive oxygen species, endoplasmic reticulum (ER) stress, hypoxia, and inflammation (11–14). Recently, adipose tissue has been taken into
Implications of suboptimal COVID-19 vaccination coverage in Florida and Texas

In July, 2021, another wave of COVID-19 began in the USA as the highly infectious delta (B.1.617.2) SARS-CoV-2 variant drove outbreaks predominantly affecting states with relatively low vaccination coverage. Some US states have shown the feasibility of rapidly achieving high vaccination coverage. Specifically, an average of 74.0% of adults had been fully vaccinated in Vermont, Connecticut, Massachusetts, Maine, and Rhode Island by July 31. By contrast, two states facing substantial delta-driven surges, Florida and Texas, had fully vaccinated only 59.5% and 55.8% of their adult residents, respectively. Here, we estimate the deaths, hospital admissions, and infections that could have been averted if Florida and Texas had matched the average vaccination pace of the top-performing states and vaccinated 74.0% of their adult populations by the end of July.

We adapted our agent-based model of SARS-CoV-2 transmission to the demography, contact patterns, and age-stratified vaccination trajectories of Florida and Texas. We further accounted for the emergence and spread of the alpha (B.1.1.7), gamma (P.1), iota (B.1.526), and delta variants, in addition to the original strain. Vaccine efficacies against infection and symptomatic and severe disease for different vaccine types, each variant, and by vaccine dosage were parameterised from clinical studies (appendix pp 4–5). The model was calibrated to the reported incidence in each state between Oct 1, 2020, and Aug 31, 2021 (appendix p 6). Using the calibrated model, we daily vaccine doses distributed to achieve 74.0% coverage of fully vaccinated adults by July 31, 2021, and continued with the associated daily rates of vaccine rollout. We then simulated the epidemiological trajectories of outbreaks in Florida and Texas and compared them with the observed cases, hospital admissions, and deaths in these two states from Dec 12, 2020, to Aug 31, 2021.

We found that enhanced vaccination would have markedly blunted the increase in cases, hospital admissions, and deaths in Florida and Texas (figure; appendix p 6). From the start of vaccination on Dec 12, 2020, until Aug 31, 2021, Florida had reported 2 221 520 COVID-19 cases and Texas had reported 2 142 833. Achieving 74.0% vaccination coverage by July 31 and continuing with the associated daily rate would have averted 664 007 additional cases (95% credible interval 419 219–848 020) in Florida and 647 906 additional cases (507 298–789 885) in Texas (appendix p 7). By Aug 31, the enhanced vaccination in Florida would have reduced hospital admissions by 61 327 (95% CrI 49 723–73 501) and deaths by 16 235 (13 243–19 473). The reduction in hospital admissions in Texas during the same period would have been 37 587 (95% CrI 31 575–44 659) and the reduction in deaths would have been 6353 (5227–7501). Collectively, these two states could have averted more than 95 000 hospital admissions and 22 000 deaths had they reached the vaccination coverage achieved by the top five states and continued at the same pace until Aug 31, 2021.

We further projected the epidemiological impact of a 50% increase in the daily vaccination rate in Florida and Texas compared with the status quo from Sept 1, 2021 (figure). By Oct 31, 2021, such acceleration of vaccination would prevent more than 26 000 cases and 1200 deaths in the two states.

Hospitals and intensive care units in several US states are currently overwhelmed by a surge in symptomatic COVID-19 illness almost entirely among unvaccinated individuals. The combination of relatively lower vaccination rates in southern and central US states, especially among younger people, is even more concerning as schools return to in-person classes and non-pharmaceutical measures such as mask wearing and physical distancing are relaxed. As the pandemic continues, efforts to increase vaccination will be crucial.